Drug: Nivolumab (Opdivo, Bristol-Myers Squibb)
Status: Approved for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after a platinum-based therapy
Significant Data:
- Based on data from CheckMate 141 trial which compared nivolumab with cetuximab (Erbitux, ImClone), methotrexate or docetaxel in patients with recurrent or metastatic SCCHN with disease progression on or within 6 months of receiving